Elizabeth Anderson
Stock Analyst at Evercore ISI Group
(2.23)
# 2,791
Out of 5,241 analysts
165
Total ratings
41.9%
Success rate
-2.97%
Average return
Main Sectors:
Stocks Rated by Elizabeth Anderson
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| OMDA Omada Health | Maintains: Outperform | $15 → $20 | $16.56 | +20.77% | 3 | May 8, 2026 | |
| MCK McKesson | Maintains: Outperform | $950 → $850 | $760.57 | +11.76% | 9 | May 8, 2026 | |
| NVST Envista Holdings | Maintains: Outperform | $30 → $33 | $23.22 | +42.12% | 6 | May 7, 2026 | |
| CVS CVS Health | Maintains: Outperform | $100 → $105 | $95.89 | +9.50% | 11 | May 7, 2026 | |
| AGL agilon health | Maintains: In-Line | $16 → $32 | $81.73 | -60.85% | 6 | May 7, 2026 | |
| ALGN Align Technology | Maintains: Outperform | $200 → $220 | $157.25 | +39.90% | 17 | Apr 30, 2026 | |
| ELV Elevance Health | Maintains: In-Line | $345 → $360 | $392.68 | -8.32% | 2 | Apr 23, 2026 | |
| TDOC Teladoc Health | Maintains: In-Line | $5 → $6 | $6.36 | -5.66% | 8 | Apr 8, 2026 | |
| PRVA Privia Health Group | Maintains: Outperform | $30 → $26 | $22.95 | +13.29% | 6 | Apr 8, 2026 | |
| LH Labcorp Holdings | Maintains: Outperform | $280 → $300 | $250.40 | +19.81% | 8 | Apr 8, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $225 → $185 | $169.12 | +9.39% | 8 | Apr 8, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $100 → $90 | $72.72 | +23.76% | 4 | Apr 8, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $50 → $45 | $54.50 | -17.43% | 4 | Apr 8, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $25 → $14 | $13.66 | +2.49% | 12 | Apr 8, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $260 → $240 | $195.20 | +22.95% | 11 | Apr 8, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: In-Line | $220 → $210 | $186.61 | +12.53% | 6 | Apr 8, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: In-Line | $30 → $25 | $18.97 | +31.79% | 11 | Apr 8, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: In-Line | $12 → $15 | $10.07 | +48.96% | 9 | Feb 27, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $50 → $55 | $36.19 | +51.98% | 2 | Feb 26, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $40 → $27 | $17.93 | +50.59% | 5 | Feb 18, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: In-Line | $4 → $3 | $1.19 | +152.10% | 9 | Oct 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: In-Line | $68 → $26 | $0.85 | +2,970.53% | 3 | Mar 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: In-Line | $35 → $15 | $1.76 | +752.27% | 3 | Mar 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: In-Line | $11 | $1.16 | +848.28% | 2 | Jan 4, 2022 |
Omada Health
May 8, 2026
Maintains: Outperform
Price Target: $15 → $20
Current: $16.56
Upside: +20.77%
McKesson
May 8, 2026
Maintains: Outperform
Price Target: $950 → $850
Current: $760.57
Upside: +11.76%
Envista Holdings
May 7, 2026
Maintains: Outperform
Price Target: $30 → $33
Current: $23.22
Upside: +42.12%
CVS Health
May 7, 2026
Maintains: Outperform
Price Target: $100 → $105
Current: $95.89
Upside: +9.50%
agilon health
May 7, 2026
Maintains: In-Line
Price Target: $16 → $32
Current: $81.73
Upside: -60.85%
Align Technology
Apr 30, 2026
Maintains: Outperform
Price Target: $200 → $220
Current: $157.25
Upside: +39.90%
Elevance Health
Apr 23, 2026
Maintains: In-Line
Price Target: $345 → $360
Current: $392.68
Upside: -8.32%
Teladoc Health
Apr 8, 2026
Maintains: In-Line
Price Target: $5 → $6
Current: $6.36
Upside: -5.66%
Privia Health Group
Apr 8, 2026
Maintains: Outperform
Price Target: $30 → $26
Current: $22.95
Upside: +13.29%
Labcorp Holdings
Apr 8, 2026
Maintains: Outperform
Price Target: $280 → $300
Current: $250.40
Upside: +19.81%
Apr 8, 2026
Maintains: Outperform
Price Target: $225 → $185
Current: $169.12
Upside: +9.39%
Apr 8, 2026
Maintains: Outperform
Price Target: $100 → $90
Current: $72.72
Upside: +23.76%
Apr 8, 2026
Maintains: Outperform
Price Target: $50 → $45
Current: $54.50
Upside: -17.43%
Apr 8, 2026
Maintains: Outperform
Price Target: $25 → $14
Current: $13.66
Upside: +2.49%
Apr 8, 2026
Maintains: Outperform
Price Target: $260 → $240
Current: $195.20
Upside: +22.95%
Apr 8, 2026
Maintains: In-Line
Price Target: $220 → $210
Current: $186.61
Upside: +12.53%
Apr 8, 2026
Downgrades: In-Line
Price Target: $30 → $25
Current: $18.97
Upside: +31.79%
Feb 27, 2026
Maintains: In-Line
Price Target: $12 → $15
Current: $10.07
Upside: +48.96%
Feb 26, 2026
Maintains: Outperform
Price Target: $50 → $55
Current: $36.19
Upside: +51.98%
Feb 18, 2026
Maintains: Outperform
Price Target: $40 → $27
Current: $17.93
Upside: +50.59%
Oct 8, 2025
Maintains: In-Line
Price Target: $4 → $3
Current: $1.19
Upside: +152.10%
Mar 16, 2022
Maintains: In-Line
Price Target: $68 → $26
Current: $0.85
Upside: +2,970.53%
Mar 2, 2022
Downgrades: In-Line
Price Target: $35 → $15
Current: $1.76
Upside: +752.27%
Jan 4, 2022
Downgrades: In-Line
Price Target: $11
Current: $1.16
Upside: +848.28%